Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Informs Crescendo Bio of Interest in Acquisition

NEW YORK (GenomeWeb News) – Myriad Genetics has informed Crescedo Bioscience of its “preliminary, non-binding interest” in acquiring the company, Myriad said in a regulatory document today.

The Salt Lake City firm informed Crescendo of its interest on Tuesday after Crescendo sent notice to Myriad on Nov. 14 that it had achieved a minimum revenue milestone, which gave Myriad the option to acquire Crescendo.

Myriad had made a $25 million investment in Crescendo in 2011 and as part of the investment Myriad received a three-year option to acquire Crescendo at its discretion. South San Francisco, Calif.-based Crescendo develops molecular diagnostic tests. Its lead product is the Vectra DA for rheumatoid arthritis.

If Myriad decides to purchase Crescendo, the purchase price will be “determined in accordance with the” merger agreement forged between the companies in 2011 concurrent with the $25 million investment, Myriad said in its document filed with the US Securities and Exchange Commission today. It added that if it buys Crescendo, it anticipates funding the deal with cash, cash equivalents, and marketable securities available on hand. As of Sept. 30 that amount was $515.6 million.

A deal would be completed during Myriad’s Fiscal Year 2014, ending June 30, it said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.